NCT01475006View on ClinicalTrials.gov

AMG 595 First-in-Human in Recurrent Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Advanced Malignant GliomaAnaplastic AstrocytomasGlioblastoma Multiforme
Interventions
DRUG

AMG 595

AMG 595 is an antibody drug conjugate that binds to EGFRvIII.

Trial Locations (4)

3052

Research Site, Parkville

45267

Research Site, Cincinnati

90024

Research Site, Los Angeles

02115

Research Site, Boston

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY